Raltitrexed
Title: Raltitrexed
CAS Registry Number: 112887-68-0
CAS Name: N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid
Additional Names: N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid
Manufacturers' Codes: ICI-D-1694; ZD-1694
Trademarks: Tomudex (AstraZeneca)
Molecular Formula: C21H22N4O6S
Molecular Weight: 458.49
Percent Composition: C 55.01%, H 4.84%, N 12.22%, O 20.94%, S 6.99%
Literature References: Folate-based inhibitor of thymidylate synthase; rapidly and extensively metabolized to its more potent polyglutamate derivatives. Prepn: L. R. Hughes, EP 239362 (1987 to ICI; Natl. Res. Dev.); idem, US 4992550 (1991 to ICI); P. R. Marsham et al., J. Med. Chem. 34, 1594 (1991). Pharmacokinetics: D. I. Jodrell et al., Cancer Chemother. Pharmacol. 28, 331 (1991). HPLC determn of metabolites in cultured cells: W. Gibson et al., Biochem. Pharmacol. 45, 863 (1993). Review of clinical toxicology: S. J. Clarke et al., Adv. Exp. Med. Biol. 338, 601-604 (1993); of mechanism of action: A. L. Jackman et al., ibid. 339, 265-276. Historical development, pharmacology, and clinical evaluation: S. J. Clarke et al., ibid. 277-287; A. L. Jackman et al., Eur. J. Cancer 31A, 1277-1282 (1995).
Properties: Pale yellow powder. Sol in water.
 
Derivative Type: Monohydrate
Molecular Formula: C21H22N4O6S.H2O
Molecular Weight: 476.50
Percent Composition: C 52.93%, H 5.08%, N 11.76%, O 23.50%, S 6.73%
Properties: mp 180-184°.
Melting point: mp 180-184°
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Antimetabolites; Folic Acid Analogs/Antagonists.

Others monographs:
HistidineMonosodium GlutamateAvoparcinPyridinium Bromide Perbromide
Silicon TetrabromidePellotineNoxythiolinDihydroxyaluminum Aminoacetate
Oxapropanium Iodideα-AntiarinGlybuthiazol(e)Napropamide
FlucytosineCyanogen IodideHydrogen SelenideNeutral Red
©2016 DrugLead US FDA&EMEA